Zenapax

Zenapax

 [ze´nah-paks]
trademark for a preparation of daclizumab, an immunosuppressant used after kidney transplantation.

Zenapax

[ze′nah-paks]
a trademark for a preparation of daclizumab, an immunosuppressant used after kidney transplantation.

Zenapax®

Daclizumab, see there.
References in periodicals archive ?
In the first penile transplantation,9 pre and intra-operative immunosuppressive induction regimens were administered [50 mg of Zenapax, 1000 mg of mycophenolate mofetil (MMF) at 1.
Drugs in development that target the immune system include rituximab, sold under the brand name Rituxan by Roche and Biogen to fight leukemia, Tysabri from Biogen and Elan , Lemtrada, sold as Campath by Sanofi's unit Genzyme for cancer, and Abbott and Biogen's Zenapax or daclizumab.
Zenapax (daclizumab), which also blocks signaling cytokines, was tested in a placebo-controlled trial of 270 people with active relapsing MS.
We believe this strategic move will permit us to maximize the potential value of Zenapax and Nuvion, as we are building significant competence ahead of our hoped for product introductions in 2007 and beyond.
A laboratory-created monoclonal antibody, Zenapax blocks the activity of a key immune activator in MS.
In an exploratory 12-month study of 55 heart transplant patients, adjunct treatment with the humanized monoclonal antibody Zenapax (daclizumab) reduced the number and severity of early organ rejection episodes, according to researchers at Columbia Presbyterian Center of New York Presbyterian Hospital.
Roche Holding AG, Basel, Switzerland, has been given approval by the European Union (EU) regulators to market Zenapax (daclizumab) for patients who have received kidney transplants.
The three other royalty-bearing products are Synagis from MedImmune, Mylotarg from Wyeth and Zenapax, marketed by Protein Design partner Hoffmann-La Roche.
described her group's study of immune responses in ten participants of a clinical trial of Zenapax in combination with interferon beta.
Other MABs still in early small-scale studies include Rituxan (rituximab), WA-J695, CNTO 1275, and Zenapax (daclizumab).
Thus we needed to use our best immunosuppression and Zenapax in combination with our other immunosuppressive agents represented that best combination.